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Fig 1. Tubular apocrine adenoma clinically and dermoscopically mimicking basal cell
carcinoma. A, A well-circumscribed black papule of 3 mm in diameter with a pearly border
on the left cheek. No ulceration is observed. B, Telangiectasias (short fine telangiectasias) and
round or oval bluish gray areas (large blue-gray ovoid nests) are observed under dermoscopy.
Note that the large blue-gray ovoid nests are arranged in a floriform pattern.
Fig 2. Tubular apocrine adenoma. Histologic findings of
the nodule. The histology of the nodule shows an intra-
dermal nodule composed of variable sized tubular struc-
tures without connection to the follicular infundibulum.
Note that numerous red blood cells are observed in the
tubular structures. (Hematoxylin-eosin stain; original
magnification 312.5.)
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e46 Letterspattern. The coexistence of SFTs and mature large
blue-gray ovoid nests and/or the peculiar arrange-
ment of the ovoid nests might be specific dermo-
scopic features of TAA. In addition to the typical
histologic features of TAA, numerous RBCs in the
tubular structures were uniquely observed in this
case (Fig 2), presumably giving an atypical color to
the lesion. Thus, we speculate that the large blue-
gray ovoid nests histologically correspond to the
tubular structures filled with numerous RBCs. SFTs
also correspond to histologic telangiectasias
observed in the upper dermis.
In summary, our case suggests that TAA could
mimic pigmented BCC clinically and dermoscopi-
cally, especially when SFTs and large blue-gray
Open access under CC BY-NC-ND license.ovoid nests in a floriform pattern are seen
dermoscopically.
Takamasa Ito, MD, Toshifumi Nomura, MD, PhD,
Yasuyuki Fujita, MD, PhD, Riichiro Abe,
MD, PhD, and Hiroshi Shimizu, MD, PhD
Department of Dermatology, Hokkaido University
Graduate School of Medicine, Sapporo, Japan
Funding sources: None.
Conflicts of interest: None declared.
Correspondence to: Toshifumi Nomura, MD, PhD,
Department of Dermatology, Hokkaido Univer-
sity Graduate School of Medicine, North 15, West
7, Kita-ku, Sapporo 060-8638, Japan
E-mail: nomura@huhp.hokudai.ac.jpREFERENCES
1. Landry M, Winkelmann RK. An unusual tubular apocrine
adenoma. Arch Dermatol 1972;105:869-79.
2. Mitsuishi T, Kawana S. Tubular apocrine adenoma of the nose.
Eur J Dermatol 2011;21:132.
3. Altamura D, Menzies SW, Argenziano G, Zalaudek I, Soyer HP,
Sera F, et al. Dermoscopy of basal cell carcinoma: morphologic
variability of global and local features and accuracy of
diagnosis. J Am Acad Dermatol 2010;62:67-75.
http://dx.doi.org/10.1016/j.jaad.2014.01.873Efficacy of oral alitretinoin for the treatment
of Darier disease: A case report
To the Editor:Darier disease (DD) is a rare hereditary
acantholytic dermatosis caused by a mutation in the
ATP2A2 gene. Skin lesions are characterized by
persistent confluent papules located over the sebor-
rheic areas of the face, chest, and back. Nails are also
commonly affected. DD has a chronic course with
Fig 1. A, Knee before treatment with alitretinoin. B, Knee after 1 month of alitretinoin
treatment.
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Letters e47frequent relapses. Its treatment is often difficult and
unsatisfactory.1 Oral acitretin is sometimes used to
treat extensive forms.2 However, this treatment is
limited by its significant adverse effects. Furthermore,
women of child-bearing potential should avoid
pregnancy during treatment and for at least 2 years
after discontinuing acitretin. We report the case of a
woman successfully treated with alitretinoin for
severe DD with frequent relapses.
A 38-year-old woman was referred to our depart-
ment for refractory DD since her teenage years.
Her mother and sister also had a medical history
of DD. Topical treatments (corticosteroids, 1%
5-fluorouracil, tazarotene gel) were ineffective.
Systemic treatment with acitretin (10 to 25 mg) was
partially effective but poorly tolerated, in that
mucocutaneous side effects (severe cheilitis and
xerosis) developed and transaminases increased
4-fold. This hepatotoxicity recurred after 1 to 3
months of treatment each time acitretin was
reintroduced.
In the 3 months before presenting to our clinic,
the patient experienced a relapse of DD with
generalized confluent warty papules. Given that
acitretin was only partially effective and was associ-
ated with considerable toxicity, we started treatment
with oral alitretinoin (30 mg/day).
Within 2 weeks, a significant improvement was
noted and complete remission was observed after 1
month (Fig 1). However, the patient decided to
interrupt treatment. DD relapsed 4 months later. A
second course of 1month of 30mg/day of alitretinoinwas again rapidly effective andwell toleratedwithout
any side effects (liver function remained normal and
there was no cheilitis or xerosis).
Alitretinoin acts as a pan-agonist for retinoid
receptors, binding with high affinity to both retinoic
acid and retinoid X receptors. Previous studies
accounted for efficacy of retinoin in DD by its effect
on cell proliferation, differentiation, keratinization,
sebum secretion, and immunomodulation,3,5 which
could also account for the efficacy of alitretinoin in
our case report. To our knowledge, to date, only 2
German teams have reported the use of alitretinoin
for the treatment of DD. In these reports, the 3
patients were treated with the same dose for more
than 4 months.1,4 In our case, after each DD
relapse, the lesions cleared quickly with alitretinoin
therapy, allowing treatment to be discontinued after
1 month.
However, our patient seemed to have less severe
DD than the German cases; thus, treatment duration
should be adapted to the clinical response.
Alitretinoin is better tolerated than other retinoids.
Because of its shorter biological half-life, contracep-
tion must be extended for only 1 month beyond the
end of the treatment (vs 2 years for acitretin). This
point makes alitretinoin easier to use for patients
with child-bearing potential. Alitretinoin may be
considered as an efficient and well-tolerated treat-
ment for severe forms of DD in young women.
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Alitretinoin: A new treatment option for
hereditary punctate palmoplantar
keratoderma (Brauer-Buschke-Fischer
syndrome)
To the Editor: Punctate palmoplantar keratoderma
type I (Brauer-Buschke-Fischer syndrome or PPKP1)Fig 1. Hereditary punctate palmoplantar keratod
lesions on left sole, coalescing to form diffuse
alitretinoin. After 8 months of therapy, lesions hais one of a group of heterogeneous disorders
characterized by abnormal keratinization of the
palms and soles. It is an autosomal dominant
genodermatosis, and lesions appear within the first
2 decades of life. Molecular genetic studies have
shown loss-of-function mutations in AAGAB, encod-
ing - and  -adaptin-binding protein p34, located at
locus 15q22.1
Since PPKP1 is a rare disease, no standardized
treatment has been established. Therapeutic ap-
proaches are based on traditional systemic retinoids
(e.g., acitretin), although a successful response is not
always seen.
We describe a 41-year-old Caucasian woman
with a 20-year history of hyperkeratotic lesions on
the palms and soles. She complained of pruritus
and pain, as well as difficulty walking and
performing manual activities. Previous treatments,
which included various keratolytic creams/
ointments and potent topical steroids, did not
produce a significant improvement. Similar
skin lesions were present in her brother and
grandmother.
Dermatologic examination demonstrated multi-
ple, yellow-gray crater-like hyperkeratotic papules
on the palms and soles. The papules coalesced to
form diffuse plaques of approximately 1 to 2 cm in
diameter, especially over pressure points on the feet
(Fig 1, A). There was no keratoderma transgrediens.
Histopathology of a skin biopsy specimen from a
palm lesion revealed marked hyperkeratosis, para-
keratosis, and mild acanthosis without any change inerma. Multiple, yellow-gray hyperkeratotic
plaques (A) before treatment with oral
d nearly completely resolved (B).
